Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shukra PharmaceuticalsBOM:524632 +0.19%66 Net Margin % is 55.09% as of Jun. 2026, which is 513% above its 10-year median of 8.98. GuruFocus rates BOM:524632 with a GF Score™ of 66/100 and a GF Value™ of ₹8.57 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Shukra Pharmaceuticals ranks better than 96.76% on this metric.
Shukra Pharmaceuticals (BOM:524632) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shukra Pharmaceuticals Net Margin % Related Terms
Shukra Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals (BOM:524632) has a Net Margin % of 55.09% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shukra Pharmaceuticals and its competitors. This is 513% above median its historical median of 8.98. Over the past decade, Shukra Pharmaceuticals' Net Margin % has ranged from 0.30 to 38.88. According to the industry distribution chart, Shukra Pharmaceuticals ranks #31 out of 958 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Shukra Pharmaceuticals' Net Margin % too high?
Shukra Pharmaceuticals' current Net Margin % of 55.09% is 513% above median its 10-year median of 8.98. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 38.88. The Drug Manufacturers industry median Net Margin % is 5.41. Shukra Pharmaceuticals' value of 55.09% is 918.3% above this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #31 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #31 out of 958 companies for Net Margin %. This places Shukra Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.41. Shukra Pharmaceuticals' value of 55.09% is 918.3% above this benchmark. Historically, Shukra Pharmaceuticals' own Net Margin % has ranged from 0.30 to 38.88 over the past decade. While the company's 10-year median is 8.98 vs. the industry median of 5.41, Shukra Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.41, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Net Margin % of 55.09% is 918.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Net Margin % is 55.09%, which is 513% above median its own 10-year median of 8.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.57, compared to a current price of ₹41.51 — trading 384.4% above its estimated fair value. The current Net Margin % is 55.09%, which is 513% above median its 10-year median of 8.98 and 918.3% above the Drug Manufacturers industry median of 5.41. Shukra Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Net Margin % is 55.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹41.51 is trading 384.4% above its estimated GF Value™ of ₹8.57.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Net Margin %: 55.09% (513% above median its 10-year median of 8.98)
GF Value™: ₹8.57 vs. price of ₹41.51 (384.4% above fair value)
Industry Position: 918.3% above the Drug Manufacturers median (#31 of 958)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
66GF Score
Get the complete analysis for BOM:524632
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
